XellSmart, a developer of stem cell treatment solutions, has raised nearly 100 million yuan ($15 million) in its pre-Series A round. In a separate development, ByteDance and Asia-focused private equity firm Hillhouse Capital have backed tech firm RiVAI in its Series A round.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
